重组人α-2b干扰素凝胶对尖锐湿疣患者免疫功能及炎症指标的影响

Effect of recombinant human interferon α-2b gel on immune function and inflammatory factors in patient with condyloma acuminatum

目的分析重组人α-2b干扰素凝胶对尖锐湿疣患者免疫功能及炎症指标的影响。方法选取2018年1月至2019年1月期间西安市鄠邑区人民医院皮肤科收治的100例尖锐湿疣患者作为研究对象,按随机数表法将患者分为对照组和观察组各50例。对照组患者在常规治疗基础上给予安慰剂治疗,观察组则在常规治疗基础上给予重组人α-2b干扰素凝胶治疗。治疗3个月后,比较两组患者的治疗效果和不良反应,同时比较两组患者治疗前后的白介素-6(IL-6)、白介素-2(IL-2)、肿瘤坏死因子-γ(TNF-γ)、干扰素-γ(INF-γ)免疫功能指标和免疫球蛋白A(Ig A)、免疫球蛋白G(Ig G)、免疫球蛋白M(Ig M)血清炎性因子的变化情况。结果观察组患者的治疗总有效率为96.0%,明显高于对照组的82.0%,差异有统计学意义(P<0.05);治疗前,两组患者的INF-γ、IL-6等血清炎性因子水平比较,差异均无统计学意义(P>0.05);治疗后,观察组和对照组患者IL-6[(7.56±1.72)ng/L vs(13.11±3.47)ng/L]、IL-2[(187.82±28.54)ng/L vs(256.80±36.61)ng/L]、TNF-γ[(4.59±0.89)ng/L vs(7.51±1.87)ng/L]及INF-γ[(15.69±3.58)ng/L vs(19.97±3.73)ng/L]比较,观察组明显低于对照组,差异均有统计学意义(P<0.05);治疗前,两组患者的IgA、IgG及IgM免疫功能指标比较差异均无统计学意义(P>0.05);治疗后,观察组和对照组患者的IgM[(1.03±0.22)g/L vs(1.38±0.29)g/L]、Ig G[(8.27±2.70)g/L vs(10.37±2.46)g/L]及Ig A[(0.55±0.34)g/L vs(0.77±0.31)g/L]相比,观察组明显低于对照组,差异均有统计学意义(P<0.05);观察组患者的治疗不良反应率为4.0%,对照组未发现不良反应。结论重组人α-2b干扰素凝胶治疗尖锐湿疣可明显改善患者的炎症状况,提高患者免疫功能,且安全可靠。

Objective To analyze the effect of recombinant human interferon α-2 b(rh IFNα-2 b) gel on immune function and inflammatory factors in patient with condyloma acuminatum. Methods A total of 100 patients, who admitted to Department of Dermatology, Huyi District People’s Hospital of Xi’an from January 2018 to January 2019 were selected and divided into the observation group and the control group, with 50 patients in each group. The control group was given placebo, while the observation group received rh IFNα-2 b gel on the conventional treatment. Therapeutic effect and adverse reactions of the two groups were observed. After 3 months of treatment, interleukin-6(IL-6), interleukin-2(IL-2), tumor necrosis factor(TNF)-α, interferon(IFN)-γ IgA, IgG, IgM of the two groups were analysed. Results The total efficiency of the observation group was 96.0% versus 82.0% of the control group(P<0.05). Before the treatment, there was no significant difference in serum inflammatory factors(INF-γ, IL-6) between the groups(P>0.05);After the treatment, IL-6, IL-2, TNF-α, IFN-γ in the observation group were(7.56±1.72) ng/L,(187.82±28.54)ng/L,(4.59 ± 0.89) ng/L,(15.69 ± 3.58) ng/L, respectively, which were significantly lower than corresponding(13.11 ±3.47) ng/L,(256.80±36.61) ng/L,(7.51±1.87) ng/L,(19.97±3.73) ng/L in the control group(all P<0.05). Before the treatment, there was no significant difference in IgA, IgG and IgM between the two groups(all P>0.05). After the treatment,IgM, IgG, Ig A in the observation group were(1.03±0.22) g/L,(8.27±2.70) g/L,(0.55±0.34) g/L, which were significantly lower than corresponding(1.38±0.29) g/L,(10.37±2.46) g/L,(0.77±0.31) g/L in the control group(all P<0.05). The total adverse reaction rate of the observation group was 4.0%, and no adverse reactions were found in the control group.Conclusion Recombinant human interferon-alpha-2 b gel can significantly improve inflammation and immune function of patients with condyloma acuminatum, which is safe and reliable.